News

Anuncio de fusión de las sociedades UXAFARMA, S.A. y ABBEY FARMA, S.L.

Publicación Proyecto Fusión de las sociedades UXAFARMA, S.A. (absorbente) y ABBEY FARMA, S.L. (absorbida) de fecha 14/05/2014, con información de los derechos que asisten a socios y acreedores de ambas sociedades, conforme a los artículos 44 y 51 de la Ley 3/2009 de 3 de abril, de Modificaciones Estructurales de las Sociedades Mercantiles.

Información adicional: Anuncio fusión UXAFARMA, S.A. y ABBEY FARMA, S.L.

Agreement with Aristo Pharma Iberia

Abbey farma and Aristo Pharma Iberia sign a cooperation agreement for the co-promotion of BRAINAL and MEGAMILBEDOCE products in the Spanish market. Brainal is a nimodipine based compound indicated in the prevention of vasospasm secondary to subarachnoid hemorrhage, a life threatening condition in the brain. Megamilbedoce is a vitamin B12 based injectable remedy indicated in a variety of clinical conditions requiring substantial availability of B12 vitamin, including anemia, enteritis, neoplasms and diabetic polyneuropathy.

Agreement with Ilitia Ginecologie

Abbey farma and Ilitia Ginecologie sign an agreement for the exclusive promotion to gynecologists of 12 products designed for women healthcare. Product list derives from the research, development and manufacturing by Ilitia and are intended to provide added value in the relief of signs and symptoms of certain gynecological processes. Remedies include inter alia: Dictyolone, Menoactive, Candiae, Uractive and Florae. See complete information on products by visiting Ilitia website: www.ilitiaginecologie.com

Agreement with Daiichi Sankyo España

Abbey farma and Daiichi Snakyo España sign an agreement for the promotion of Trosid in Spain. Abbey will be responsible for the presentation of product to physicians. Trosid, a tioconazole based product, is indicated in the treatment of onycomicosis (fungal infections in the nails) caused by dermatophytes and sensible yeasts. Daiichi Sankyo received contractual rights for the commercialization of Trosid in Spain granted by Pfizer España, the research company owner of tiaconazole and marketing holder of Trosid in Spain.